Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results
09. Mai 2017 08:00 ET
|
Aeglea BioTherapeutics
AUSTIN, Texas, May 09, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting
29. März 2017 16:05 ET
|
Aeglea BioTherapeutics
AUSTIN, Texas, March 29, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics to Present at the 16th Annual Needham Healthcare Conference
28. März 2017 16:05 ET
|
Aeglea BioTherapeutics
AUSTIN, Texas, March 28, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
23. März 2017 16:05 ET
|
Aeglea BioTherapeutics
-- Topline Results Presented Today of Phase 1 Open-Label Study of AEB1102 Enzyme Replacement Therapy in Adult Patients with Arginase I Deficiency -- -- Conference Call Today at 4:30 p.m. ET to...
Aeglea BioTherapeutics to Present Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency at 2017 ACMG Annual Clinical Genetics Meeting
23. März 2017 08:00 ET
|
Aeglea BioTherapeutics
AUSTIN, Texas, March 23, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results on Thursday, March 23
17. März 2017 08:00 ET
|
Aeglea BioTherapeutics
AUSTIN, Texas, March 17, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at Keystone Symposia Conference on Tumor Metabolism
28. Februar 2017 08:00 ET
|
Aeglea BioTherapeutics
AUSTIN, Texas, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics Appoints Dr. Suzanne Bruhn to Board of Directors
16. Februar 2017 16:01 ET
|
Aeglea BioTherapeutics
AUSTIN, Texas, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics to Present New Data at 2017 ACMG Annual Clinical Genetics Meeting
17. Januar 2017 16:00 ET
|
Aeglea BioTherapeutics
AUSTIN, Texas, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics to Present at BMO Capital Markets Prescription for Success Healthcare Conference
07. Dezember 2016 08:00 ET
|
Aeglea BioTherapeutics
AUSTIN, Texas, Dec. 07, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...